Immune function of successfully treated lymphoma patients.

Abstract

A B S T R A C T Immunologic function was evaluated in 12 patients with Hodgkin's disease and 5 patients with lymphocytic lymphoma who had been successfully treated with either chemotherapy, radiation therapy, or both of these modalities 3-42 mo previously. Only two of the patients were found to have total anergy to a battery of six recall skin test antigens and all were responsive to skin testing with phytohemagglutinin. However, 10 of 16 patients were unable to develop delayed cutaneous hypersensitivity to either of the neoantigens dinitrochlorobenzene or keyhole limpet hemocyanin. Four other patients developed reactivity to only one of these neoantigens for a total of 14 of 16 (88%) of the patients demonstrating some impairment in neoantigen response.Total lymphocyte, T-lymphocyte, B-lymphocyte, and null cell numbers, as well as serum immunoglobulins were quantitatively normal. Monocyte numbers, chemotaxis, and Fc receptor activity were normal. Monocyte staphylocidal activity at 60 min was modestly depressed and candidacidal activity was depressed in those receiving both chemotherapy and radiation therapy.Spontaneous (unstimulated) lymphocyte [8H]thymidine incorporation was low in the patients as a group and lymphoblastic transformation to specific antigens was impaired in 11 of 17 patients who had positive skin test reactions to the same antigen. Highly significant suppression of lymphoblastic transformation was noted after stimulation by the mitogens phytohemagglutinin, pokeweed, and concanavalin-A. The greatest impairment of mitogen response was seen in those patients receiving both chemotherapy and radiation therapy.

Eosinophilia in Hodgkin’s Disease: A Role for Interleukin 5

“…3). This observation con firms previous reports from other investigators [10][11][12][13]. In vitro cytokine production, including IL-2, GM-CSF, y-IFN, and the release of sCD23 were also diminished in HD pa tients, suggesting a decreased Type 1 T cell function in these patients.…”

Association of depressed postoperative lymphoproliferative responses to alloantigens with poor prognosis in patients with stage I lung cancer

“…Depressed LP responses in cancer patients have been described in many studies (Ducos et al, 1970;Rees et al, 1975;Han and Takita, 1972;Catalona et al, 1973;Dean et al, l977,1978Dean et al, l977, ,1979aLiebler et al, 1977;Dalbrow et al, 1977;Hersh and Oppenheim, 1965;Cohnen et al, 1973;Graze et al, 1976;Faquet, 1975;MelIstedt and Holm, 1973;King et al, 1976;Matchett et al, 1973;Garrloch et al, 1970;McKhann et al, 1975;Golub et al, 1974;Whittaker et al, 1971;Weese et al, 1977). However, LP responsiveness did not always correlate well with stage of disease and therefore appeared to be independent of extent of tumor burden (Bornes et al, 1975).…”

Lymphocyte function in untreated Hodgkin's disease: An important predictor of prognosis

“…Some facets of the immunodeficiency seem to be associated with active disease. Thus, the lymphocyte stimulation by recall antigen in vitro and in vivo, and to some extent the spontaneous lymphocyte DNA synthesis, may eventually normalize (Sokal & Primikirios, 1961;King et al, 1976;Gobbi et al, 1977;Bjorkholm et al, 1977bBjorkholm et al, , c, 1981. Lymphocyte inhibitory serum factors which disappear after successful treatment may contribute to the deficiency during active disease (Holm et al, 1979a, b).…”